欢迎访问百泰生物药业有限公司!

站内搜索: 商品

   20世纪70年代,单克隆抗体这一名词开始出现,科学家们意识到它可以针对肿瘤特异性分子进行严厉打击,这一发现也逐渐引发癌症治疗的新变革。作为中国生物制药的企业——百泰生物药业有限公司,从1999年起,开始尝试单克隆抗体药物在癌症治疗领域的临床应用。在2008年4月,泰欣生(尼妥珠单抗)正式上市,它是一个以EGFR为靶点的人源化单抗药物。

您现在的位置:首页 >> 医患之家 >> 学术进展 >> 尼妥珠单抗靶向治疗不可切除的头颈部癌的初步研究(摘要)

尼妥珠单抗靶向治疗不可切除的头颈部癌的初步研究(摘要)

日期:2016年1月18日 21:31

Pilot study of target therapy with EGFR antibody (Nimotuzumab) in patients with unresectable head and neck cancer
W. Guo*, Guoxin REN,Chaojun LI,Yunteng WU
    Dept.of Oral and Maxillofacical Surgery, 9th People’s Hospital,School of Medicine, Shanghai Jiaotong University, 200011, China
[Abstract]
    Background: Nimotuzumab, a humanized anti-EGFR monoclonal antibody, has demonstrated well tolerate anti-cancer efficacy. Therefore, we designed this study to explore the efficacy of the combination of biological target therapy (utilize Nimotuzumab) and chemotherapy with unresectable neck and head carcinomas.
    Material and Methods: 71 patients (54 men and 17 women, age 30–83 years, mean 60) were enrolled in this study. All patients had locally advanced oral-maxillofacial and head and neck tumours (no indication for surgery or radiotherapy) confirmed by histology and radiology, with indication for biochemotherapy. The chemotherapy regimen given was cisplatin 75mg/m2 day 1, paclitaxel 75mg/m2 day 1, fluorouracil 750mg/m2 days 1–5, and Nimotuzumab 200mg/m2 weekly.
    Results: Patients completed 2–4 cycles of chemotherapy (mean 2.2). Nimotuzumab was given 2–8 times (mean 4.3). The prognosis was as follows: complete response in 4 patients, partial response in 39, stable disease in 18, and progressive disease in 3. 7 patients could not be evaluated. The total effective rate, calculated as complete plus partial responses, was 61%. 29 patients had surgery after biochemotherapy. No serious adverse reactions were noted during the course of the treatment, only one case of slight erythra infection.
    Conclusions: Nimotuzumab was equally effective in the increase of chemosensitivity and good tolerability profiles.
Key words: target therapy; EGFR antibody; Nimotuzumab; head and neck cancer
Abstract number: E16-0515

所属类别: 学术进展

该资讯的关键词为:

在线留言
请留下您的宝贵意见或建议及联系方式(邮箱或电话),方便我们能及时回复您!
 
留言内容:
* 已输入字符:0
小于等于500字符
验证码:
   
联系我们
如果您有相关的合作意向,请您来电咨询或电邮cooperation@biotechplc.com !

泰欣生咨询热线:400-659-2330
公司总机:010-51571020
传 真:010-51571026
邮 编:100176
地 址:中国北京经济技术开发区荣京东街2号
学术微信:靶向治疗与精准医学 账号:zlbxzl